Abbott's second-quarter earnings showed a mixed bag with pandemic disruptions on the medical device side of the business, and sales of COVID-19 tests driving growth for the diagnostic side.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,